Avidity Biosciences is delivering a new class of RNA therapeutics called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat rare muscle diseases, such as Myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), Facioscapulohumeral Muscular Dystrophy (FSHD) and Pompe Disease.

This page is intended to serve as notice under 35 U.S.C.§ 287(a).

Myotonic dystrophy type 1 (DM1) Drug Candidate AOC 1001:

• U.S. Pat. No 10,881,743
• U.S. Pat. No 10,913,800
• U.S. Pat. No 11,028,179
• U.S. Pat. No 11,246,941